Dr. Kate Salters
Today, July 28th, is World Hepatitis Day, a day to raise awareness of the global burden of viral hepatitis and also to influence meaningful change in delivering care to those living with the virus. The theme this year is ‘Hepatitis Can’t Wait’.
BC is committed to achieving the World Health Organization’s target of eliminating hepatitis C by 2030. Health Minister Adrian Dix addressed this goal in Legislature last month, citing the $142.44 million spent in 2019-2020 for medications to treat the hepatitis C virus (HCV) in British Columbia.
HCV treatment has improved considerably, evolving from poorly tolerated interferon-based therapies towards newer curative, oral, direct acting antiviral (DAA) based therapies. The new DAA therapy can achieve cure rates greater than 95% after just 8 to 12 weeks. In BC treatment is free for all eligible patients with chronic HCV.
Despite these remarkable advances, there are nearly 30,000 people in BC living with untreated HCV. Many have been previously diagnosed but lost to follow-up care, and this population may also experience various forms of social and economic marginalization. People who are living with HIV and HCV may experience unique vulnerabilities. Recent BC-CfE findings presented at this year’s CAHR conference indicate that women and people living with HIV (PLWH) with a history of injection drug use are less likely to be treated for HCV (vs men and people who don’t use drugs). The needs and realities of women and PLWH with a history of injection drug use must be considered in health service delivery to ensure equitable care and treatment for all. This is particularly relevant as the BC-Centre for Disease Control recently reported that about 85% of new HCV infections in the province are related to injection drug use, and a smaller number to unprotected anal sex and drug use. HCV has also been documented to disproportionately impact Indigenous people and people born in endemic countries, who may have difficulties accessing health care services
The BC Centre for Excellence in HIV/AIDS (BC-CfE) is internationally recognized as a leader in the fight against HIV/AIDS and related epidemics, including HCV. In 2019, the BC-CfE opened an integrated, low-barrier primary care clinic and research and innovation facility, called the Hope to Health (H2H) Complex, in the heart of Vancouver’s Downtown East side (DTES). The DTES neighbourhood is home to about 18,000 people, and estimates of HCV within the community are as high as 90%. In mid-2020, the BC-CfE launched a safer drug supply program and in October 2020 a Supervised Consumption Site (SCS) within the H2H Complex.
To address these health inequities, a new 12-month pilot project at the H2H complex has been designed to support HCV education, testing, and access to care among people who use drugs in the DTES. Gaps in testing, linkage to care and treatment uptake for people living with HCV who use drugs represents a considerable impediment to controlling the HCV epidemic in Canada.
Offering these services in a setting designed to prioritize the health and well-being for people who use drugs is an important part of our effort to optimize access to HCV treatment to prevent HCV disease progression and HCV transmission at once
– Dr. Julio Montaner, Executive Director, and Physician in Chief, at the BC-Centre for Excellence in HIV/AID.
Dr. Kate Salters, the newly appointed BC-CfE’s HCV-Treatment as Prevention¨ (TasP¨) Project Coordinator, is leading the BC-CfE’s efforts to control the HCV epidemic among hard-to-reach populations in BC. Dr. Salters is a Research Scientist with the BC-CfE’s Epidemiology and Population Health program and her research focuses on health care engagement and health outcomes among people living with HIV and HCV.
At H2H, Dr. Salters and her team ensure everyone who visits the SCS or is part of the safer drug supply program is offered an HCV test at least once; provide all clients with education about HCV, including steps to reduce risk of acquiring or transmitting HCV; follow-up with all clients through peer and nursing support; and offer treatment to all eligible and interested patients who are diagnosed with HCV on site and support retention and end-of-treatment follow-up through peer and nurse engagement.
Often HCV is considered to be less of a priority by health care, vs more pressing needs like mental health or substance use, but untreated HCV will transition into chronic HCV disease in about 85% of cases, which can in turn lead to liver cancer or cirrhosis. Efforts to seek, test, treat and retain in care people living with HCV cannot wait.
Dr. Salters notes,”As we have learned over the last 16 months, public health cannot just consider one public health issue at a time. We need public health responses and research that acknowledges convergent and mutually aggravating epidemics and must consider new approaches that prioritize needs of patients and meet them where they are at.”
-30-
About the British Columbia Centre for Excellence in HIV/AIDS
The BC Centre for Excellence in HIV/AIDS (BC-CfE) is Canada’s largest HIV/AIDS research, treatment and education facility – nationally and internationally recognized as an innovative world leader in combating HIV/AIDS and related diseases. The made-in- BC Treatment as Prevention¨ strategy (TasP¨ ) pioneered by BC-CfE, and supported by UNAIDS since 2011, inspired the ambitious global target for HIV treatment – known as the 90-90-90 Target – to end AIDS as a pandemic by 2030. The BC-CfE is applying TasP¨ to therapeutic areas beyond HIV/AIDS, including viral hepatitis and addiction, to promote Targeted Disease Elimination¨ as a means to contribute to healthcare sustainability. The BC-CfE works in close collaboration with key stakeholders, including government, health authorities, health care providers, academics, and the community to decrease the health burden of HIV/AIDS, hepatitis C and addictions across Canada and around the world.
For more information, please contact:
Edmond Chu
Communications Coordinator, BC-CfE
Cell: 236-885-4617
Email: echu@bccfe.ca
HCV FACTS
- The Guidelines and Protocols Advisory Committee (GPAC), an advisory committee to BC’s Medical Services Commission with representatives from both the Doctors of BC and the Ministry of Health, recently approved revisions to the BC Viral Hepatitis Testing Guideline. These changes mean BC is now the first province or territory in Canada to recommend one-time birth cohort screening for people born between 1945 and 1965. As this birth cohort accounts for nearly 60% of positive hepatitis results in BC, many of whom remain undiagnosed and have not had confirmatory HCV RNA testing, it represents a key population that needs to be engaged in HCV care to reduce liver disease complications.
- Approximately 85% of new HCV infections relate to injection drug use
- Populations with a disproportionately high burden of HCV infection in BC include Indigenous people, people born in endemic countries, and people who are incarcerated (PWAI).
- Patient-provider knowledge gaps, stigma, racism, unemployment, unstable housing, and poverty intersect in populations affected by HCV in BC, resulting in reduced access to HCV care. Health equity can be fostered by engaging and including people from affected groups in the creation and implementation of new policies and guidelines.
- 75% of people living with Hep C in BC were born between 1945-1975.
- The BCCDC recommends HCV testing for everyone at least once.
- People can live with hepatitis C for many years without knowing because they do not look or feel sick. The only way to know if you are infected is to get a blood test.
- Although there are some cases where HCV can clear without treatment, this is rare. A blood test is the only way to confirm if you have or had HCV.
- You can still become re-infected with hepatitis C even after completing treatment and successfully clearing the virus from your blood.
- HCV cannot be spread by hugs, handshakes and coughing. Hepatitis C is usually only spread through blood-to-blood contact.
- The old treatment, Interferon, which was used to treat HCV has been replaced with DAAs which cause little to no side effects.
- DAA treatment consists of one pill each day and the typical course is only 12 weeks with a 95% cure rate.
- Who is at risk for hepatitis C virus?
- Those who have had a blood transfusion before 1992
- Ever used IV drugs
- Have high-risk sex (multiple partners, history of STIs)
- Live with or care for someone who has HCV
- Were born between 1945-1975